Bristol Myers Squibb News

23.12 / 13:23

UPS Provident Booking Pool show Schools Introverts want the boss to understand their plight

Subscribe to enjoy similar stories. “Passion doesn’t have to look like ‘rah, rah!’" Bristol-Myers Squibb employees were giving managers pointers on how to tell whether their introverted staffers are excited about their work. After all, it can be hard to tell.

03.04 / 00:53

markets UPS FIVE Manufacturing Research hospital patient Wockhardt pins US future on novel antibiotics, vacating US generics biz

Subscribe to enjoy similar stories. Wockhardt Ltd that built its name as a maker of generic drugs is shifting its focus in the US market to developing new antibiotics, turning away from generics and entering a space largely vacated by Big Pharma in recent years. The company is working on new antibiotics and has identified segments for a push into biosimilar drugs, chairman Habil Khorakiwala said, in the wake of promising results shown by Zaynich, an antibiotic it developed in-house.

02.02 / 03:27

COST Strategy Software Gemini Enterprise information Features No one knows how to price AI tools

Subscribe to enjoy similar stories. More than two years after the public debut of ChatGPT, software companies still haven’t found a compelling way of charging for AI tools, chief information officers say. Now they’re trying new strategies.

02.12 / 22:03

CEO Align Research patient medicines rights Pharmaceuticals Better drugs through AI? Insitro CEO on what machine learning can teach Big Pharma

Artificial intelligence is changing the way industries do business

31.10 / 19:15

BLOCK Research show voice testing patient medicines A promising schizophrenia drug showed mixed results. What does that mean for patients?

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research

27.06 / 07:27

markets Target CEO wellness patient Videos Pharmaceuticals CEO in major health-advertising fraud gets 7.5-year prison sentence

CHICAGO—Tech entrepreneur Rishi Shah was sentenced to seven-and-a-half years in prison Wednesday for his part in what prosecutors called a billion-dollar fraud scheme centered on video advertisements in doctors’ offices. Federal Judge Thomas Durkin said Shah, former chief executive and co-founder of startup Outcome Health, had undermined the integrity of the markets. “The only deterrence to white-collar crime or any kind of crime is jail," he said.

09.05 / 09:27

markets SUN WhatsApp wellness reports Pharmaceuticals Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales

generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market. Consolidated profit rose to 1.78 billion rupees ($21.3 million) in the three months ended March 31, from 1.53 billion rupees a year earlier.

01.03 / 18:43

Merck Pfizer President cover Courts Headlines Third US judge upholds Medicare drug price negotiation program

By Brendan Pierson

23.01 / 09:05

Target Progressive CEO Healthcare Trade Equality rights France's Sanofi to buy US drugs project INBRX-101 for about $2.2 billion

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion in a bid to boost its rare disease business. The two companies said in a joint statement on Tuesday that Inhibrx shareholders will get $30 per share in cash, one contingent value right (CVR) equal to $5, and 0.25 shares in New Inhibrx, a new publicly traded company that holds the takeover target's assets that are not related to INBRX-101.

26.12 / 18:28

Midday movers: Intel, RayzeBio, and more

Investing.com – Main U.S. indexes climbed on light volume the day after the Christmas holiday as hopes the Fed will begin lowering interest rates in the first quarter of next year lifted sentiment.

26.12 / 15:44

Merck Immunic show testing recommendations patient medicines Rethinking Immunotherapy for Cancer: When Is the Best Time to Stop?

Immune-boosting drugs have revolutionized cancer care. Now doctors are experimenting with cutting them off. Immunotherapies unleash the immune system on tumors.

26.12 / 13:35

Target CEO song Bristol-Myers Squibb to buy RayzeBio for $4.1 billion

Pharmaceutical giant Bristol-Myers Squibb (NYSE:BMY) announced Tuesday that it is acquiring RayzeBio (RYZB) for $4.1 billion, strengthening its oncology portfolio with promising radiopharmaceutical therapeutics (RPTs).

24.12 / 17:10

FIVE Manufacturing economy NetEase show reports week Stock market today: Wall Street ticks closer to record highs to cap its 8th straight winning week

Wall Street closed its eighth straight winning week with a quiet finish following reports showing inflation on the way down and the economy potentially on the way up

24.12 / 17:02

CEO Pfizer Healthcare Bill President prevention acquires Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

22.12 / 17:43

Cummins NetEase ANSYS reports Midday movers: Nike, Karuna Therapeutics and more

Investing.com – Main U.S. indexes rose Friday in light volume ahead of the Christmas holiday as inflation data lifted hopes the Fed will begin lowering interest rates in the first quarter of next year.

22.12 / 13:52

reports Bristol-Myers Squibb to acquire Karuna for $14 billion

Bristol Myers Squibb (NYSE:BMY) has agreed to a deal to acquire neuroscience-drug developer Karuna Therapeutics (NASDAQ:KRTX) for $14 billion, the two companies said.

04.12 / 22:21

Progressive Pfizer Bayer patient Blackstone explores sale of Anthos Therapeutics -sources

By David Carnevali

28.11 / 14:16

Manufacturing Adobe Boeing Avid Bill Pinduoduo reports Affirm, Canada Goose, PDD and Avidity rise premarket; Zscaler falls

Investing.com — U.S. futures traded largely flat Tuesday, as investors awaited details of retail sales on Cyber Monday as well as more comments from a number of Fed officials.

26.10 / 14:21

Airlines Software Align Hasbro Mattel Overstockcom reports Stocks making the biggest moves before the bell: Hasbro, Southwest, Hershey, Royal Caribbean and more

Check out the companies making headlines in premarket trading.

09.10 / 17:09

UPS Amazon Airlines Motorola Stocks making the biggest moves midday: General Dynamics, United Airlines, Spotify and more

In this article

09.10 / 14:53

UPS Target CEO Enterprise Nov Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal

By Michael Erman

information about Bristol Myers Squibb

Who is Bristol Myers Squibb?

Bristol Myers Squibb is a public personality featured in various informative articles related to recent developments.

Why is Bristol Myers Squibb attracting attention?

Bristol Myers Squibb frequently draws public interest due to noteworthy actions, which raises concern among experts and the public.

Where can I find the latest news about Bristol Myers Squibb?

Our website has a dedicated section featuring all publications related to Bristol Myers Squibb. We continuously monitor developments and update the information as it becomes available.